Cetix

Quick links to important sections

Cetix

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cetix

Property Description
Active ingredient Cetirizine Hydrochloride
Form Tablets, oral solutions, drops
Pharmacological class Selective peripheral H1-receptor antagonist
Common use Systemic relief of allergic manifestations
Origin Synthetic compound

Cetix is a pharmaceutical preparation whose therapeutic effect is driven by the active ingredient, Cetirizine Hydrochloride. It is scientifically classified as a second-generation antihistamine, a class of medicine that is clinically recognized for providing systemic relief for allergic manifestations. The medicine operates as a selective peripheral Histamine H1-receptor antagonist, which means its primary function is to directly interrupt the chemical signals that trigger physical allergy symptoms.

Its inclusion on the World Health Organization's List of Essential Medicines affirms its global recognition for safety and efficacy in treating allergic conditions. This global listing indicates that the medication is considered an effective and necessary therapeutic agent for managing public health needs, such as providing relief for symptoms of seasonal allergy flares.


Composition, Origin, and Available Forms

The therapeutic action is attributed entirely to the component, Cetirizine Hydrochloride, which is a specific dihydrochloride salt. This compound is synthetic, having been derived as a metabolite of hydroxyzine, and it functions as a single-component therapeutic agent.

For patient convenience, Cetix is formulated for the oral route of administration and is typically provided in several common oral dosage forms, including film-coated tablets, oral solutions, and drops. The availability of these preparations ensures that the systemic delivery of the active ingredient remains accessible for a diverse patient population.


Defining the Action: How Does Cetirizine Differ from Older Treatments?

The defining characteristic of Cetirizine as a second-generation compound is its selective peripheral action. This selectivity is key because it limits the compound's ability to significantly affect the central nervous system, unlike earlier, first-generation antihistamines.

This difference in chemical mechanism allows Cetirizine to provide effective anti-allergic action by blocking histamine at target sites while substantially reducing the likelihood of common unintended effects, such as drowsiness or sedation. By offering this targeted mechanism, Cetirizine provides reliable symptomatic control and is a modern standard for controlling immediate hypersensitivity reactions.

Regulatory References

  1. WHO Model List of Essential Medicines

What side effects are possible with Cetix?

Possible Side Effects and Safety Information

Cetix (cefixime) is a cephalosporin antibiotic with a defined safety profile documented in regulatory sources.

Adverse Reactions Summary

Common (occurring in 1% to <10% of patients): The most frequently reported adverse reactions are gastrointestinal disturbances, including diarrhea (up to 16% in some trials), nausea, loose stools, abdominal pain, dyspepsia, and vomiting.

Serious and Clinically Significant Reactions (Rare to Very Rare):

  • Hypersensitivity: Severe acute reactions, including anaphylactic/anaphylactoid reactions (with shock and fatalities), and angioedema, require immediate discontinuation of the drug.
  • Severe Skin Reactions: Serious Cutaneous Adverse Reactions (SCARs) such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) have been reported.
  • Gastrointestinal: Clostridium difficile-Associated Diarrhea (CDAD) and colitis, which can range from mild to life-threatening.
  • Nervous System: Seizures and encephalopathy (including confusion, impairment of consciousness, and movement disorders) have been noted, particularly in the presence of overdose or renal impairment.
  • Hemic/Lymphatic: Blood disorders such as drug-induced hemolytic anemia, agranulocytosis, and transient changes in white blood cell and platelet counts.

Safety Considerations and Restrictions

Contraindications: The use of Cetix is contraindicated in patients with a known hypersensitivity to the active substance, cefixime, or to any other cephalosporin antibiotic. Caution is necessary for patients with a history of penicillin hypersensitivity due to the risk of cross-allergenicity.

Population/Dose: Dosage adjustment is required for patients with markedly impaired renal function. Cefixime may enhance the effects of coumarin-type anticoagulants (e.g., warfarin), necessitating prothrombin time monitoring. Safety and efficacy have not been established in children younger than six months.

Overdose and Emergency Response

Overdose and When to Seek Help

Regulatory documents define overdose primarily as an extension of known effects, affecting the Central Nervous System (CNS) and potentially the cardiovascular system. Due to the risk of severe complications, all suspected cases require immediate medical attention.

Documented Manifestations

The most commonly documented signs of overdose include CNS depression, such as somnolence, dizziness, and fatigue, with somnolence noted to be dose-related. Other reported signs are dry mouth, diarrhoea, and nausea. In pediatric cases, initial symptoms may include restlessness or irritability before progressing to sedation.

Severe Outcomes and Emergency Action

Officially reported severe outcomes associated with high-dose exposure include tachycardia (rapid heart rate), convulsions, syncope (fainting), and urinary retention. Because of the potential for these serious manifestations, emergency services or a Poison Control Center must be contacted right away, even if symptoms appear mild. Individuals with pre-existing renal impairment are at increased risk of toxicity due to the drug’s elimination profile.

Overdose Management

Management of Cetix overdose is restricted to symptomatic and supportive treatment. Regulatory information explicitly states that no specific antidote is known and that the active ingredient is not effectively removed by dialysis. This limitation underscores the critical need for immediate clinical monitoring to manage any systemic complications.

Therapeutic Uses of Cetix

The medication is generally used to provide support that helps ease the overall symptom burden related to heightened physiological activity caused by common allergens. It is applied across therapeutic domains where additional symptomatic support is needed, assisting patients to cope more steadily with difficult episodes.

The medication is considered relevant when supportive symptom management is appropriate for conditions characterized by periods of heightened symptoms, such as seasonal and perennial allergic rhinitis, chronic urticaria (hives), and allergic conjunctivitis. This application is considered relevant in managing symptoms that create noticeable interference with daily functioning.

The primary benefit involves symptomatic management for the physical manifestations of allergy. “It helps address symptom clusters that may become intense or disruptive, supporting patients during difficult episodes by easing distress.”

The drug plays a role in managing symptoms that interfere with routine activities, including persistent sneezing, excessive runny nose (rhinorrhea), intense pruritus (itching of the skin and nose), and uncomfortable watery eyes. It contributes to easing the overall symptom load during flares or from constant, year-round indoor allergens, while assisting with maintaining functional stability.

Quick Fact: Relief for Allergic Skin and Mucosal Irritation is typically sought during phases of increased distress or when symptoms become temporarily overwhelming, and supports general well-being during symptomatic phases.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Cetix

Cetix (referring to the active substance Cetirizine) is an antihistamine. Official regulatory documents define clear populations who must not use this medicine (contraindications) and those for whom use is restricted or requires professional consultation.

Category Regulatory Status (Use is Prohibited/Restricted)
Contraindicated Use is prohibited in patients with severe kidney disease (severe renal failure with creatinine clearance below 10 mL/min).
Contraindicated Use is prohibited if there is a known hypersensitivity (allergy) to the active substance, any inactive ingredients, hydroxyzine, or any piperazine derivatives (related substances).
Age Restriction Use in children under 6 years of age is not recommended for certain formulations (e.g., tablets) due to the inability to achieve appropriate dose adaptation.
Condition-Specific Patients with moderate kidney disease or those with predisposing factors for urinary retention (such as spinal cord injury or prostate problems) must consult a doctor, as a lower dose may be necessary.
Physiological State Use while breast-feeding is not recommended, and pregnant women should consult a health professional before use.

For all other populations not subject to these specific contraindications or warnings, the medicine is generally allowed when indicated. Any patient with pre-existing liver or kidney conditions must seek medical advice before starting treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile of Cetix, defined by government regulatory documents, is structured around specific pharmacodynamic, pharmacokinetic, and procedural findings. The drug does not have any formal contraindications based on drug-drug interactions.

Pharmacodynamic Interactions and Restrictions

Co-administration with alcohol and other central nervous system (CNS) depressants, such as sedatives and tranquilizers, is subject to regulatory caution. Official labeling states that this combination may cause an additive pharmacodynamic effect resulting in additional reductions in alertness and impairment of performance.

Pharmacokinetic Modifications and Clearance

A documented pharmacokinetic finding involves co-administration with Theophylline (400 mg once daily), which results in a small but measurable 16% decrease in the clearance of cetirizine. The medicine's absorption is affected by food, which delays the rate of absorption but does not reduce the overall extent of exposure. Clearance is also officially documented as decreased and half-life prolonged in the geriatric population and in patients with established hepatic or renal impairment, potentially leading to increased systemic exposure.

Procedural Constraints

A timing-based restriction applies to the use of the medicine before specific diagnostic testing: Cetix must be discontinued for several days before an allergy skin test to prevent the suppression of the required cutaneous histamine response.

Mechanism of Action

How Cetix Works: Mechanism of Action

Selective Blocking of Histamine H1 Receptors

This core mechanistic domain involves the drug acting as a competitive antagonist primarily at the peripheral Histamine H1 Receptor (H1R). By occupying these receptors, Cetix prevents the binding of the natural inflammatory mediator, histamine, which in turn suppresses the molecular signaling cascade that histamine would otherwise initiate.

Effect on Vascular Permeability and Peripheral Pathways

This domain covers the downstream consequences of H1 receptor blockade, focusing on the drug's effect on tissue response. The mechanism influences processes where the release of histamine leads to the widening of blood vessels and increased vascular permeability (leakiness). This action restricts the downstream signaling of histamine on surrounding tissues. Crucially, its mechanism is highly peripheral, as the drug poorly crosses the blood-brain barrier.

Effect on Histamine-Mediated Physiological Responses

The overall mechanism engages signaling sequences that normally drive fluid leakage and smooth muscle contraction in response to histamine. By modifying these early molecular steps, the action modifies the physiological responses driven by histamine and affects the histamine-driven inflammatory systems, which determines the drug's physiological effect profile.

Dosage and Administration Information

How to Use Cetix

Cetix (Cetirizine Hydrochloride) administration is governed by standardized protocols that specify dose, frequency, and necessary adjustments. The medicine is primarily taken via the oral route as tablets or solutions, though an Intravenous (IV) injection is an approved method for a specific injectable product. The medicine may be taken with or without food, as food intake does not significantly affect the total absorption of the drug. Dosing is standardized as a single administration event every 24 hours.


Standard Administration and Dosing

Population Standard Daily Dose Maximum Dose
Adults & Adolescents 10 mg once daily 10 mg per 24 hours
Older Adults 5 mg once daily (starting dose) 10 mg per 24 hours

Population-Specific Adjustments

Mandatory dose modifications are required for certain physiological conditions, as Cetix is predominantly eliminated by the kidneys. For patients with severe renal impairment (creatinine clearance < 30 mL/min), the dose is reduced to 5 mg once every two days to account for the prolonged half-life. For children aged 6 to 12 years, standard regulatory schedules often specify a divided dose of 5 mg twice daily.


Procedural Conditions

Liquid formulations must be accurately measured using a proper dosing device supplied with the product. If a dose is missed, the protocol is to skip the missed dose and take the next dose at the regular time; a double dose should not be taken to compensate. The medicine is used for symptomatic administration and may be administered for either short or long-term management.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cetix


## Research Evidence for Seasonal Allergic Rhinitis (Hay Fever)

The evidence base for Cetix in seasonal allergic rhinitis primarily involves numerous Randomized Controlled Trials (RCTs). These studies were evaluated in research exploring how symptoms change over time when participants are experiencing conditions associated with acute or disruptive episodes during high allergy seasons. Researchers monitored outcomes related to physical discomfort, such as sneezing, runny nose, and itchy eyes, and used scores to examine symptom intensity or variability. Trials were observed in various populations, including Adults, Adolescents, and Children (2 years and older).

The findings from these structured studies describe patterns observed in the data related to short-term observation. Studies conducted during periods of increased symptom activity reported how symptoms evolved in the observed populations compared to control groups. This research describes short-term changes and contributes to the body of information regarding how patients reported their experience during brief, seasonal episodes.

It is important to understand that the assessment periods for these acute seasonal studies were generally short-term, typically lasting one to two weeks. Therefore, long-term effects are not fully established through this specific clinical trial data. The evidence contributes to the overall research data for conditions involving episodic or acute changes in allergy symptoms.


## Research Evidence for Chronic Hives (Urticaria)

For chronic hives (urticaria), the clinical evaluation included Randomized Controlled Trials alongside specialized pharmacodynamic studies. The research explored outcomes related to the physical manifestations of chronic skin conditions where symptoms may vary in intensity. Research examined outcomes linked to inflammatory or irritative states, focusing specifically on objective measures like the size and count of hives (wheals) and patient-reported outcomes describing perceived discomfort (itching).

Trial data described measured outcomes related to physical discomfort. Research conducted during periods where symptoms become more noticeable reported how the measured symptom intensity evolved in the observed populations. Regulatory reviews have utilized these findings, which are based on established clinical trial methods, in their assessment of short-term data for this condition.

The research primarily focuses on symptom monitoring over short-term periods (a few days to 4 weeks). Consequently, the studies focus on symptoms and do not address underlying disease mechanisms. Evidence for long-term use and the impact on overall disease progression is limited to findings from post-marketing analyses and general clinical experience rather than dedicated, long-duration trials.


## Research Evidence for Perennial Allergic Rhinitis (Year-Round Allergies)

The evaluation of Cetix for perennial allergic rhinitisconditions characterized by fluctuating or episodic manifestations throughout the year due to constant exposure to allergens—used a framework of intermediate-term Randomized Controlled Trials. Research described studies monitoring physiological strain or stress in populations like Adults, Children (including infants as young as 6 months), and adolescents. The outcomes captured phases of heightened symptom activity, such as nasal congestion and rhinorrhea, and also assessed changes in daily functioning or activity level.

Studies reported how symptoms evolved in the observed populations across defined time intervals. The findings showed patterns related to the measured outcomes for symptoms that are present year-round. This evidence contributes to the broader data by observing responses over defined time intervals in settings with varying symptom burdens.

While evidence is extensive for intermediate-term observation, there is limited information for long-term outcomes characterizing the effects of continuous use over several years. Additionally, some studies involving the youngest patient populations (infants) used modest sample sizes compared to adult trials, which can appear to introduce some uncertainty into the findings for that specific demographic.


## Investigational Studies in Specialized Pediatric Subgroups

Cetix was studied for a highly specific research question: exploring the potential for delaying or preventing the onset of asthma in a narrow group of infants who already had Atopic Dermatitis (eczema) and were sensitized to common allergens. This research involved specialized, long-term Randomized Controlled Trials (RCTs) focusing on changes in functional outcomes and disease development over observational periods lasting up to 36 months.

The principal trial monitored outcomes and showed patterns related to the cumulative incidence of asthma between the study groups only within a specific, pre-defined subgroup of highly sensitized infants. In the overall study population, including children without specific allergen sensitization, findings were mixed regarding asthma onset.

The results apply only to the populations studied and are not generalizable to the broader pediatric population. Data are still emerging, and further replication studies are usually recommended to substantiate these observations.


## Evidence in Special Populations and Long-Term Follow-up

The main research programs for Cetix were evaluated in various special populations, including a broad range of Children (starting from 6 months of age) and Older Adults. The evidence base contains trials that monitored outcomes related to physical discomfort in these diverse age groups. Studies involving children and infants are generally included in the overall evidence profile for both seasonal and perennial allergic rhinitis.

Regarding long-term follow-up, the follow-up durations were limited in many of the core efficacy trials, particularly those for acute relief of seasonal symptoms. Therefore, long-term effects are not fully established through dedicated, multi-year randomized trials. Research for perennial conditions included intermediate-term observation, but most evidence related to effects lasting longer than a year comes from regulatory safety reviews and post-marketing surveillance, not from primary long-term efficacy trials.


## Scientific Gaps and Areas of Research Uncertainty

While a large amount of evidence contributes to the overall research data for Cetix, certain limitations are noted in the scientific literature. Evidence quality varies across studies, particularly when comparing the earliest clinical data to more recent, standardized trials.

Data for certain groups remain insufficient, especially for very long-term outcomes tracking continuous use over many years in the general population. Furthermore, in the youngest pediatric populations (under 2 years), sample sizes were modest in some specific indication trials, which can introduce some uncertainty into the findings for those groups. The specialized research focusing on asthma onset results apply only to the specific populations studied, leaving the question as an area where further study is needed for the wider at-risk infant population.

Frequently Asked Questions (FAQ)

Common questions about Cetix (FAQ)

Q: Is Cetix the same type of medicine as [similar drug name]? What's the difference?

Official documents classify Cetix as a second-generation antihistamine. This class of medicine is known for its selective peripheral action, meaning it primarily targets allergy signals in the body but poorly crosses the blood-brain barrier. This difference in mechanism is why it is often associated with less sedation than older types of allergy medication.

Q: Are there any long-term effects associated with using Cetix?

Official regulatory reviews summarize that the primary efficacy data comes from short-term trials. However, after years of post-marketing surveillance, the official Warnings and Precautions section has not identified a specific long-term safety concern or risk associated with continuous use.

Q: What should I know about Cetix and driving or operating machinery?

The official regulatory text advises caution regarding driving and operating hazardous machinery. Patients are advised to avoid these activities if they experience side effects such as drowsiness, dizziness, or impaired alertness when taking Cetix.

Q: Does Cetix affect sleep or cause drowsiness?

According to regulatory documents, drowsiness (or somnolence) is listed as a common side effect. The official information indicates that the frequency of this effect may increase if the medicine is taken at doses higher than those recommended.

Q: Are there any dietary restrictions or foods to avoid while taking Cetix?

Official regulatory data confirms that Cetix can be taken with or without food. While food may slightly delay the rate of absorption of the medicine into the body, the overall amount absorbed does not appear to be significantly altered.

Q: Can older people use Cetix?

Official documents confirm that use in older adults is permitted when indicated. Regulatory information notes that a lower starting dose may be necessary in this population because the medicine's clearance from the body is often slower.

Q: What kind of studies have been done on the safety of Cetix?

Safety information for Cetix is compiled from multiple sources. These include pre-clinical studies (like toxicology research), continuous monitoring of adverse events in controlled clinical trials, and ongoing reviews of post-marketing surveillance reports submitted by the public and healthcare professionals.

Q: Does Cetix affect the results of common blood tests?

Official documents require the medicine to be discontinued for a specific period before conducting an allergy skin test to prevent suppressing the test results. Separately, transient changes in blood counts are listed as rare side effects in the safety information.

Q: Are there different strengths or forms of the Cetix medicine?

The official product information states that Cetix is available in multiple forms to accommodate different patients. These generally include 5 mg and 10 mg tablets, as well as liquid formulations such as oral solutions or drops.

Q: What is the pregnancy risk category for Cetix?

According to the US regulatory framework, Cetix is classified as a Pregnancy Category B drug. This classification indicates that while animal reproduction studies have not demonstrated a risk to the fetus, there have been no adequate and controlled studies conducted in pregnant women.

Q: What are the official uses of Cetix in different countries like the UK or Japan?

Official regulatory documents from various countries, such as the UK or Japan, list the specific approved indications. These typically include the relief of symptoms associated with perennial allergic rhinitis (year-round allergies), seasonal allergic rhinitis (hay fever), and chronic urticaria (hives).

Q: What is the success rate of Cetix in clinical trials?

Research evidence describes the effectiveness of Cetix in terms of achieving statistically significant improvements compared to a placebo. Studies track changes in specific symptom scores, such as the severity of sneezing, nasal discharge, itching, and the size or count of hives.

Q: Do I need a prescription for Cetix everywhere?

Regulatory and health authority documents describe Cetix as being available both as a prescription medicine and, in many regions, as a non-prescription over-the-counter medicine. The availability status can vary depending on the local jurisdiction and regulatory body.

Q: Are there any specific warnings for people with liver disease taking Cetix?

Official documents state that no dose adjustment is typically necessary for those with isolated liver impairment. However, caution is advised because the medicine's clearance from the body may be prolonged when liver issues are present.

Q: Does Cetix make other medicines more or less potent?

Regulatory information indicates that combining Cetix with other medicines can have two general outcomes. This may lead to additive effects (such as increased central nervous system depression) or cause decreased clearance of Cetix from the body, which could prolong its action.

Q: Are there any studies focusing on long-term safety of Cetix?

Information regarding long-term safety is gathered from regulatory reviews of post-marketing surveillance data. This data is collected from extended observation periods within pre-approved clinical trials and reports from the public and health professionals.

Q: What is the main reason doctors prescribe Cetix?

According to official product information, Cetix is primarily indicated for the relief of symptoms related to seasonal and perennial allergic rhinitis (hay fever and year-round allergies). It is also indicated for the treatment of uncomplicated skin manifestations of chronic idiopathic urticaria (hives).

Q: How quickly can I expect Cetix to start working?

Regulatory information indicates that the onset of action for Cetix is generally rapid. Effects of the medicine are often reported within 1 hour following a single administration.

Q: Does Cetix cause weight gain or weight loss?

Regulatory data identifies weight gain as an adverse reaction that has been reported in clinical trials or through post-marketing experience. Patients concerned about weight changes may review the full list of reported adverse reactions in the official product information.

Q: Can I take Cetix if I am already taking common pain relievers?

Official documents do not typically list specific interactions with common over-the-counter pain relievers. However, regulatory information generally cautions patients about combining Cetix with any medicine that causes central nervous system depression (sedation or relaxation).

Q: Is it true that Cetix is less effective after a long period of use?

Studies have examined the risk of developing tolerance, which is a decrease in effectiveness over time. Evidence from official sources indicates that no clinically relevant tolerance has been observed in studies reviewed to date when the medicine is used for prolonged periods at the recommended dose.

Q: Is it normal to feel a change in mood or energy when starting Cetix?

Official documents list adverse reactions such as agitation, depression, irritability, and insomnia in the safety section. These symptoms are recognized as possible effects that may be perceived as a change in mood or energy level.

Q: What is the risk of dependence or withdrawal symptoms with Cetix?

Official labeling for Cetix generally does not include information on drug abuse or dependence, indicating that it has no official classification as a substance with significant potential for abuse or dependence.

Q: How long does Cetix stay in your system?

According to official documents, the average time it takes for half of the medicine to be cleared (the elimination half-life) is approximately 8 to 10 hours in adults with normal kidney function. This rate is noted to be longer in patients with kidney impairment.

Q: Does taking Cetix mean I need to avoid sunlight?

The official label generally does not list photosensitivity or phototoxicity as a common or serious adverse reaction. Photosensitivity is an increased skin reaction to sunlight, and it is not typically noted in the safety profile for Cetix.

Q: Can I take Cetix if I have a history of heart issues?

Official regulatory documents do not list heart conditions as a specific contraindication (a reason to prohibit use) or warning in the product information. Eligibility for use is generally described in the product information.

Q: Can Cetix be split or crushed, according to official instructions?

The regulatory information for the specific tablet formulation is the definitive source. Most tablets are not scored or recommended for splitting or crushing unless the official label explicitly includes instructions for modifying the dosage form.

Q: Does Cetix affect fertility or hormone levels?

Animal studies have examined the potential for adverse effects on fertility and reproduction. Regulatory reviews noted that no impairment was observed in these studies when the drug was administered at recommended therapeutic exposures.

Q: Is it common for Cetix to cause a headache?

According to official documents, headache is described as a common side effect. It was reported to occur in 1% to <10% of patients during clinical trials.

Q: Is there evidence that Cetix is addictive?

Official labeling for Cetix states there is no known evidence suggesting that the drug is addictive. It is not classified as a controlled substance with potential for abuse in regulatory listings.

Q: Can a person with diabetes safely use Cetix?

Regulatory documents generally do not list diabetes as a specific contraindication or special warning in the product information. Cetix is not typically associated with effects on blood sugar control.

Q: Does Cetix interact with birth control pills?

Clinical studies have investigated the potential for interaction with oral contraceptives (birth control pills). Official documents conclude that no clinically significant interaction was found in studies reviewed by regulatory agencies between the two medicines.

Q: Is it necessary to finish the entire course of Cetix as prescribed?

Because Cetix is indicated for the symptomatic relief of allergic conditions, the duration of use is typically determined by the patient's symptoms and allergen exposure. Unlike some other medicines, its use is generally administered as needed for symptom control, as prescribed by a healthcare provider.

How should Cetix be stored and disposed of?

Storage and Disposal Requirements for Cetix

Cetix (Cetirizine Hydrochloride) must be stored under specific environmental and temperature controls as defined by regulatory documents to maintain stability and effectiveness.

Storage Requirement Official Condition
Temperature Controlled Room Temperature (20 C to 25 C), avoiding excessive heat above 40 C.
Protection Store protected from light and in a location that avoids high humidity.
Container Do not use if the tamper-evident safety seal is broken or missing.
Safety Keep the medicine strictly out of the sight and reach of children.

For disposal, unused or expired Cetix must not be discarded into wastewater or standard household waste to protect the environment. The product must be disposed of according to the specific local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cetix found in:

A-Z Index: